Geert Van Gils

%22I bring 25+ years of global life sciences experience at the intersection of commercial strategy and operational execution — spanning oncology, immunology, and cell & gene therapy. I%27ve built commercial organizations from the ground up, led complex multi-market launches across Europe, managed P&Ls of €100M+, and steered organizations through the full asset lifecycle from late-stage development to portfolio divestment. My rare combination of C-suite commercial leadership and a deep finance foundation means I don%27t just challenge strategy — I challenge the assumptions behind it.%22

Why I add value on a board
- Commercial & Finance Fluency — Career spanning EMEA Finance Director to VP Commercial makes me uniquely effective at interrogating business cases, forecasts, and capital allocation.
- Advanced Therapy Expertise — Hands-on experience building ATMP commercial infrastructure in Europe
- Launch Readiness Oversight — Pattern recognition across multiple blockbuster launches enables early identification of execution risk before it becomes shareholder risk.
- Alliance & Partnership Governance — Seasoned in co-commercialization complexity; understands where partnerships create value and where they create risk.
- European Market Depth — Genuine EU5 & EMEA operational experience, invaluable for US or Asian biotechs building or stress-testing European strategy.

Where I%27m most impactful:
- Pre-commercial Biotech (EU): Launch readiness, go-to-market design, market access strategy
- US/APAC Biotech entering Europe: EMEA commercial build-out, reimbursement navigation
- Cell & Gene Therapy Companies: ATMP commercial infrastructure, supply & access model design
- Specialty Pharma with BD Activity: Commercial due diligence, asset prioritization
- Co-commercialization Ventures: Alliance governance, execution alignment
PE/VC-backed Life Sciences - Value creation planning, commercial transformation
- Start ups in lifesciences